AZD-9291 (Mesylate)
Inquiry
Post Date: | Jun 06,2020 |
Expiry Date: | Jun 06,2021 |
Detailed Description: |
Cas No. :1421373-66-1
Quantity: 1Metric Tons Specs:99%min Osimertinib mesylate Basic information Product Name: Osimertinib mesylate Synonyms: Mesylate-AZD9291;Osimertinib Mesylate (Tagrisso, Mereletinib, AZD-9291);Osimertinib d6;N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate;Osimertinib methanesulfonate;Osimertinib (AZD9291) mesylate;Mereletinib mesylate, 98%, a potent and selective mutated forms EGFR inhibitor;AZD-9291 mesylate (Osimertinib mesylate CAS: 1421373-66-1 MF: C28H33N7O2.CH4O3S MW: 595.71298 EINECS: 200-064-1 Product Categories: API;AZD09 Mol File: 1421373-66-1.mol Osimertinib mesylate Structure Osimertinib mesylate Chemical Properties Safety Information HS Code 29339900 MSDS Information Osimertinib mesylate Usage And Synthesis Definition ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Used for treatment of EGFR T790M mutation positive non-small cell lung cancer. Indications The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee. |
CAS Registry Number: | 1421373-66-1 |
Synonyms: | ;Osimertinib mesylate;N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1);Osimertinib Mesylate;AZD-9291 mesylate; |
Molecular Formula: | C28H33N7O2.CH4O3S |
Molecular Weight: | 595.71 |
Molecular Structure: |
Company: | shanghai missyou chemical co.,ltd. |
Contact: | eileen zhang |
Tel: | +86-18101936766 |
Fax: | 021-58583907 |
Email: | eileen@shmychem.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.